Search Results
Your search for ,aLl matches 18308 pages
Showing 1401 - 1450How Accurate Is Staging in Early Pancreatic Cancer?
Staging may be inaccurate in up to 80% of patients with early pancreatic cancer, according to a recent study published by Perrotta et al in JAMA. The findings underscored the need for advancements in diagnostic technology and staging, which may help to improve early pancreatic cancer treatment and...
Study Supports Universal Genetic Testing of Newly Diagnosed Patients With Invasive Breast Cancer
In a cross-sectional study reported in JAMA Network Open, Rezoug et al found that universal genetic testing identified immediately actionable and established germline pathogenic variants in more than 1 in 20 newly diagnosed patients with invasive breast cancer and was associated with systemic...
Prostate Cancer Mortality and 5-ARI Use
In a Canadian study reported in JAMA Network Open, Hamilton et al found that use of 5-alpha reductase inhibitors (5-ARIs) prior to the diagnosis of prostate cancer was not associated with an increased risk of prostate cancer–specific or overall mortality. Study Details The study involved data from...
Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults
Imagine walking into a fancy restaurant only to find a menu consisting mostly of kids’ dishes. It would make no sense. Just 25% of restaurant diners are younger than age 12, and they rarely write Yelp reviews. But when it comes to cancer treatment, this is not very far from what we do. The median...
A Diagnosis of Triple-Negative Breast Cancer Was Not on My Radar
Despite the fact that there is no history of breast cancer in my family, I didn’t take that good fortune for granted and was diligent about getting my regularly scheduled mammograms and clinical breast exams, which never found any hint of disease. So, it was especially frightening when, while on a...
IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting
It happened! We received the International Development and Education Award (IDEA) from Conquer Cancer®, the ASCO Foundation, and it was a journey of growth, global collaboration, leadership, mentorship, and more. We have much to share after this breakthrough in our careers. The ASCO Annual Meeting...
Sacituzumab Govitecan in Cisplatin-Ineligible Advanced Urothelial Cancer After ICI Therapy
In cohort 2 of the phase II TROPHY-U-01 study, reported in the Journal of Clinical Oncology, Petrylak et al found that sacituzumab govitecan-hziy was active in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer progressing after immune checkpoint inhibitor (ICI)...
Immune Checkpoint Inhibitor–Related Cardiotoxicity in Patients With Cancer
In a meta-analysis reported in JAMA Oncology, Nielsen et al estimated the risk of cardiotoxicity associated with immune checkpoint inhibitor (ICI) treatment of cancers. Study Details The meta-analysis included 83,315 unique patients in 589 unique trials of ICIs and ICI combination therapies. The...
Fam-Trastuzumab Deruxtecan-nxki in Unresectable or Metastatic HER2-Positive Solid Tumors
On April 5, 2024, fam-trastuzumab deruxtecan-nxki (T-DXd) was granted accelerated approval for adults with unresectable or metastatic HER2-positive (immunohistochemistry 3+) solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.1 Supporting...
New Collaborative Guideline Highlights the Importance of Multidisciplinary Care for Patients With Osteoradionecrosis
A joint guideline from the International Society of Oral Oncology–Multinational Association for Supportive Care in Cancer and ASCO seeks to fill a gap in the clinical guidance for patients with head and neck cancers who develop osteoradionecrosis following their head and neck radiation therapy.1...
Nivolumab Plus Chemotherapy Extends Survival in Lymph Node–Only Metastatic Urothelial Cancer
The combination of nivolumab plus gemcitabine/cisplatin chemotherapy achieved high response rates and durable responses and improved overall survival and progression-free survival compared with gemcitabine/cisplatin chemotherapy alone in patients with urothelial carcinoma and clinical evidence of...
Chinese Study Finds Radiation Alone May Be as Effective as Chemoradiation in Patients With Low-Risk Nasopharyngeal Cancer
Nasopharyngeal carcinoma is an aggressive malignant head and neck cancer that is highly prevalent in the southern and southwestern provinces of China. Although the incidence of the cancer is less than 1 per 100,000 in Europe, the United States, and the Pacific,1 data from the International Agency...
Delays in Oral Antimyeloma Treatment Initiation: Role of Social Determinants of Health
A retrospective cohort study published in Blood Cancer Journal by Gasoyan et al revealed discrepancies between the timing of the initiation of any treatment and the fill of prescriptions for oral antimyeloma medications in patients with multiple myeloma, with a lower likelihood of Black and older...
Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Clinical trials are now demonstrating the value of immune checkpoint inhibitors as neoadjuvant therapy in certain subsets of patients with hormone receptor–positive, HER2-negative breast cancer. Hope S. Rugo, MD, FASCO, described this newer approach—specifically, which subsets of patients may...
Prescription for Progress: Lancet Oncology Commission’s Practical Strategies for Global Cancer Surgery
In certain regions of the world, cancer claims more lives than HIV, tuberculosis, and malaria combined, yet surgery has been relegated to the sidelines of global health initiatives. This critical need to address global inequities in access to safe, timely, and affordable cancer surgery led to the...
T-DXd Effective for Breast Tumors With HER2-Low and HER2-Ultralow Expression in Earlier Line of Therapy
In patients with hormone receptor–positive metastatic breast cancers with HER2-low or HER2-ultralow expression, treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was found to be superior to chemotherapy after one or more lines of endocrine therapy. In...
Adjuvant Pembrolizumab vs Placebo in Stage III Melanoma: Long-Term Health-Related Quality of Life
In an analysis from the phase III EORTC 1325-MG/KEYNOTE-054 trial reported in The Lancet Oncology, Bührer et al found that adjuvant pembrolizumab was not associated with significant differences in long-term health-related quality of life (HRQOL) compared with placebo in patients with stage III...
What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?
For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C group 5 member D (GPRC5D). Which is the preferred target? This question was addressed at the 2024...
Impact of Breast Cancer Screening Interval on Stage at Diagnosis and Overall Survival
Annual mammographic screening appeared to be associated with a reduced risk of late-stage breast cancer and an overall survival benefit across clinical and demographic subgroups of patients older than age 40, according to an observational analysis reported by Zuley et al in the Journal of Clinical...
Genomic Determinants of Relapse in Childhood ALL
In a study reported in the Journal of Clinical Oncology, Chang et al identified potential genomic determinants of relapse risk in pediatric acute lymphoblastic leukemia (ALL). As stated by the investigators, “Although cure rates for childhood ALL exceed 90%, ALL remains a leading cause of cancer...
Ruxolitinib for Corticosteroid-Refractory Sclerotic Chronic GVHD
In a phase II study reported in the Journal of Clinical Oncology, Vijaya Raj Bhatt, MS, MBBS, and colleagues found that ruxolitinib produced responses in patients with corticosteroid-refractory sclerotic chronic graft-vs-host disease (GVHD) after transplantation for hematologic malignancies. Study ...
HPV Vaccination Rate Among Young Female Patients With Psychiatric Diagnoses
The rate of human papillomavirus (HPV) vaccination may be lower among female individuals with mental health issues or neurodevelopmental conditions compared with their peers, according to a recent study published by Hu et al in The Lancet Public Health. Background The HPV vaccine is capable of...
FDA Approves Cancer Biomarker Test, Companion Diagnostic Indications
The U.S. Food and Drug Administration (FDA) has approved the in vitro diagnostic TruSight Oncology (TSO) Comprehensive test and its first two companion diagnostic indications. This targeted sequencing panel interrogates over 500 genes to profile a patient's solid tumor, helping to increase the...
Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer
In an Austrian study reported in the Journal of Clinical Oncology, Brunner et al identified the incidence of medication-related osteonecrosis of the jaw over 20 years of follow-up in patients with breast cancer who had bone metastases and were receiving antiresorptive medication. Study Details and...
Cancer Has Robbed Me of My Fertility and My Olympic Dreams
I was a track and field athlete throughout college, and my goal was to try out for the Olympics, but cancer had other plans for me. In 2010, while in my senior year in college, I began having sharp, shooting pains in my shoulders, which I initially attributed to overzealous training. But the pain...
Olaparib May Be Effective Without Hormone Therapy in Some Men With Biochemically Recurrent Prostate Cancer
Olaparib may be effective in treating men with biochemically recurrent prostate cancer without accompanying hormone therapy, according to a novel study published by Marshall et al in JAMA Oncology. Background Although most men with localized prostate cancer can be cured with surgery or primary...
Ponatinib With Chemotherapy for Newly Diagnosed Philadelphia Chromosome–Positive ALL
On March 19, 2024, ponatinib (Iclusig) was granted accelerated approval for use with chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL).1 Ponatinib is a multitargeted kinase inhibitor. Supporting Efficacy Data and How It Is Used Approval ...
Disparities in Exposure to Tobacco Content on Streaming Platforms
The risk of encountering tobacco products being advertised, marketed, or promoted on streaming services based on race, ethnicity, socioeconomic status, and smoking habits was identified in a recent study published by Onyeaka et al in JAMA Network Open. Background The World Health Organization...
The Evolving Epidemiology of Gastrointestinal Stromal Tumors in Major Organ Sites
Based on a descriptive, U.S. population–based cohort study reported in JAMA Network Open by Alvarez et al, over the past 2 decades, the incidence of gastrointestinal stromal tumors in major organ sites has increased among several patient populations. The findings may assist in directing future...
Inoperable Stage III NSCLC: Adaptive Radiotherapy Based on FDG-PET Tumor Residual Uptake
In a French phase II study (RTEP7–IFCT-1402) reported in The Lancet Oncology, Vera et al found that adaptive radiotherapy based on fluorine F-18–labeled fluorodeoxyglucose (FDG)–positron-emission tomography (PET) residual uptake appeared to improve local disease control compared with standard...
Targetable Variant Found in Chinese Patients With Ovarian Cancer
Researchers may have uncovered the germline mutational landscape of Chinese patients with ovarian cancer and identified an enriched RAD51D variant in these patients, according to a recent study published by Feng et al in JCO Global Oncology. The findings could serve as a critical reference for...
Role of Patient-Reported Outcome Measures in Assessing Chemotherapy-Induced Peripheral Neuropathy
A cohort study reported in JAMA Network Open by Li et al demonstrated the superiority of patient-reported outcome measures vs other methods in assessing nerve damage in patients with cancer who underwent neurotoxic chemotherapy. “Accordingly, the adoption of chemotherapy-induced peripheral...
First-Line Nivolumab/Relatlimab vs Nivolumab/Ipilimumab in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the...
Can Mindful Breathing Reduce the Intensity of Cancer-Related Pain?
Twenty minutes of mindful breathing, which focuses a person’s attention on their breath, seems to rapidly reduce the intensity and unpleasantness of cancer pain and relieve the associated anxiety, suggest findings from a small comparative study published by Tan et al in BMJ Supportive &...
Acalabrutinib Plus Chemoimmunotherapy Improves Progression-Free Survival in Older Patients With Mantle Cell Lymphoma
Combining Bruton’s tyrosine kinase (BTK) inhibition with chemoimmunotherapy induction significantly extended progression-free survival for older patients with mantle cell lymphoma, and there was also a trend toward improvement on the overall survival benefit, according to data presented during the...
SCOTUS Ruling Upends Country’s Regulatory Framework, Threatens to Complicate and Delay Health-Care Delivery
The Association for Clinical Oncology (ASCO) has serious concerns about the impact of the Supreme Court’s rulings in Loper Bright Enterprises v Raimondo and Relentless, Inc. v Department of Commerce on cancer care. These decisions overturned the “Chevron deference” or “Chevron doctrine,” a legal...
ASCO Guideline Update Highlights the Importance of Early Integration of Palliative Care for Patients With Cancer
Growing awareness of the benefits of palliative care in patients with cancer has prompted ASCO to update its recommendations for clinicians, patients, caregivers, and health-care organizations on integrating palliative care in oncology.1 The updated guideline reinforces prior recommendations in the ...
Exercise Program May Improve Symptoms, Quality of Life in Patients With Metastatic Breast Cancer
Researchers have shown that participating in an exercise program may improve pain, fatigue, and the quality of life in patients with metastatic breast cancer, according to a recent study published by Hiensch et al in Nature Medicine. Background “Although there’s substantial evidence for the...
An Integrated Approach to Treating Cancer and Cardiovascular Disease: When Oncologists and Cardiologists Collaborate
At the 2024 Debates and Didactics in Hematology and Oncology Conference, sponsored by Emory’s Winship Cancer Institute, cardiologist-by-training Anant Mandawat, MD, FACC, briefly reviewed how the emerging field of cardio-oncology is blazing a path toward “bigger and bolder cancer care” and offered...
Detecting Residual Disease After Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma
Although esophageal cancer in the United States is relatively rare, affecting about 22,400 people each year and making up about 1% of all cancer cases,1 the disease is common in East and Central Asia countries. Nearly 90% of patients with esophageal cancer in Asia are diagnosed with the squamous...
Gift of Truth: Reflections on a Father’s Cancer Journey
It was a hot and humid Tuesday in July, and I distinctly remember being grateful for the air conditioning in the pastel-shaded waiting room of the oncology outpatient clinic. My father sat silently beside me. We knew this room well, as we did the doctor we had arrived to see. He had been my...
Age Is Just a Number: Treatment Considerations for Endometrial Cancer in Older Women
Endometrial cancer is most frequently diagnosed among women aged 55 to 65, with a median age at diagnosis of 64 years.1 In epidemiologic studies, women diagnosed with endometrial cancer at an older age are more likely to have high-grade disease, aggressive histology, deep myometrial invasion, lower ...
Patients With Rare Cancers May Face Increased Risk of Anxiety and Depression
The risk of developing mental health issues may be higher among patients who have rare cancers compared with those who have common cancers, according to a recent study published by Low et al in eClinicalMedicine. Background Rare cancers—those affecting fewer than 6 out of 100,000 individuals per...
What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?
Is the optimal first-line treatment of chronic lymphocytic leukemia (CLL) monotherapy with a Bruton’s tyrosine kinase (BTK) inhibitor or some combination regimen? This clinical question was explored by two speakers at the 2024 Pan Pacific Lymphoma Conference, sponsored by the University of...
High-Risk Localized HCC: Efficacy of Neoadjuvant Immunotherapy vs Upfront Surgery
Hepatocellular carcinoma is the most common type of primary liver cancer, accounting for about 80% of all primary liver cancers in the United States, and is currently the sixth most common cancer and the fourth most common cause of cancer-related deaths. Although immunotherapy is now a mainstay for ...
Cancer Mortality Among Adults With Learning Disabilities
Investigators have found that adults with learning disabilities may be more likely to die from cancer compared with those in the general population, according to a recent study published by Ward et al in BMJ Open. Background Many cancers are considered either preventable or treatable. However,...
Mouthwash-Based Test May Help Predict Head and Neck Cancer Recurrence
Researchers have examined whether a mouthwash-based test could detect biomarkers to help physicians predict disease recurrence in patients with head and neck cancer, according to a recent study published by Franzmann et al in JAMA Otolaryngology–Head & Neck Surgery. Background Head and neck...
Are Some Uterine Tumors More Aggressive in Black Patients?
Researchers have discovered that uterine serous carcinoma tumors in Black patients tend to express more aggressive and immunosuppressive features than tumors in White patients, according to a recent study published by Foley et al in Proceedings of the National Academy of Sciences. Uterine serous...
Recurrent or Advanced Endometrial Cancer: Atezolizumab Plus Chemotherapy
As reported in The Lancet Oncology by Nicoletta Colombo, MD, and colleagues, the phase III AtTEnd trial showed improved progression-free survival with the addition of atezolizumab to chemotherapy in patients with recurrent or advanced endometrial cancer, particularly among those with mismatch...
Novel Insights May Transform Diagnosis and Treatment of Pediatric Patients With T-Lineage ALL
Researchers have uncovered that T-lineage acute lymphoblastic leukemia (ALL) may be frequently driven by genetic changes in noncoding portions of the DNA, according to a recent study published by Pölönen et al in Nature. The investigators believe these findings may lead to a paradigm shift in...
